REFERENCES
1. Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol 2023;20:404-17.
4. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell 2023;186:243-78.
5. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194-217.
6. Partridge L, Fuentealba M, Kennedy BK. The quest to slow ageing through drug discovery. Nat Rev Drug Discov 2020;19:513-32.
7. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
8. Brundel BJJM, Ai X, Hills MT, Kuipers MF, Lip GYH, de Groot NMS. Atrial fibrillation. Nat Rev Dis Primers 2022;8:21.
9. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
10. Camm AJ, Naccarelli GV, Mittal S, et al. The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review. J Am Coll Cardiol 2022;79:1932-48.
11. Dye CA, Skeete J, Khan A, et al. The era of rhythm control: a review of the epidemiology and clinical impact of anti-arrhythmic medications in atrial fibrillation. Pharmacoepidemiology 2023;2:81-97.
12. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American heart association. Circulation 2020;142:e214-33.
13. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498.
14. Brooks S, Metzner A, Wohlmuth P, et al. Insights into ablation of persistent atrial fibrillation: Lessons from 6-year clinical outcomes. J Cardiovasc Electrophysiol 2018;29:257-63.
15. Jaakkola S, Lip GY, Biancari F, et al. Predicting unsuccessful electrical cardioversion for acute atrial fibrillation (from the AF-CVS Score). Am J Cardiol 2017;119:749-52.
16. Lahiri SK, Aguilar-Sanchez Y, Wehrens XHT. Mechanisms underlying pathological Ca2+ handling in diseases of the heart. Pflugers Arch 2021;473:331-47.
17. Biliczki P, Boon RA, Girmatsion Z, et al. Age-related regulation and region-specific distribution of ion channel subunits promoting atrial fibrillation in human left and right atria. Europace 2019;21:1261-9.
18. Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res 2014;114:1483-99.
19. Turdi S, Fan X, Li J, et al. AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. Aging Cell 2010;9:592-606.
20. Qin F, Siwik DA, Lancel S, et al. Hydrogen peroxide-mediated SERCA cysteine 674 oxidation contributes to impaired cardiac myocyte relaxation in senescent mouse heart. J Am Heart Assoc 2013;2:e000184.
21. Guo KK, Ren J. Cardiac overexpression of alcohol dehydrogenase (ADH) alleviates aging-associated cardiomyocyte contractile dysfunction: role of intracellular Ca2+ cycling proteins. Aging Cell 2006;5:259-65.
22. Gergs U, Mangold W, Langguth F, et al. Alterations of protein expression of phospholamban, ZASP and plakoglobin in human atria in subgroups of seniors. Sci Rep 2019;9:5610.
23. Salameh A, Dhein S, Fleischmann B, et al. The aging heart: changes in the pharmacodynamic electrophysiological response to verapamil in aged rabbit hearts. J Physiol Pharmacol 2010;61:141-51.
24. Isenberg G, Borschke B, Rueckschloss U. Ca2+ transients of cardiomyocytes from senescent mice peak late and decay slowly. Cell Calcium 2003;34:271-80.
25. Valdés Á, Treuer AV, Barrios G, et al. NOX inhibition improves β-adrenergic stimulated contractility and intracellular calcium handling in the aged rat heart. Int J Mol Sci 2018;19:2404.
26. Zhu X, Altschafl BA, Hajjar RJ, Valdivia HH, Schmidt U. Altered Ca2+ sparks and gating properties of ryanodine receptors in aging cardiomyocytes. Cell Calcium 2005;37:583-91.
27. Wongcharoen W, Chen YC, Chen YJ, et al. Aging increases pulmonary veins arrhythmogenesis and susceptibility to calcium regulation agents. Heart Rhythm 2007;4:1338-49.
28. Cooper LL, Li W, Lu Y, et al. Redox modification of ryanodine receptors by mitochondria-derived reactive oxygen species contributes to aberrant Ca2+ handling in ageing rabbit hearts. J Physiol 2013;591:5895-911.
29. Marx SO, Marks AR. Dysfunctional ryanodine receptors in the heart: new insights into complex cardiovascular diseases. J Mol Cell Cardiol 2013;58:225-31.
30. Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci USA 2006;103:511-8.
31. Uchinoumi H, Yang Y, Oda T, et al. CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. J Mol Cell Cardiol 2016;98:62-72.
32. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 2004;94:e61-70.
33. Campbell HM, Quick AP, Abu-Taha I, et al. Loss of SPEG inhibitory phosphorylation of ryanodine receptor type-2 promotes atrial fibrillation. Circulation 2020;142:1159-72.
34. Mendonca N, Ling S, Bedja D, et al. Dysregulation of cardiac CaMKII pathway is increased in aging and chronic inflammation. FASEB J 2021;35.
35. Beavers DL, Landstrom AP, Chiang DY, Wehrens XH. Emerging roles of junctophilin-2 in the heart and implications for cardiac diseases. Cardiovasc Res 2014;103:198-205.
36. Beavers DL, Wang W, Ather S, et al. Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization. J Am Coll Cardiol 2013;62:2010-9.
37. Munro ML, Jayasinghe I, Wang Q, et al. Junctophilin-2 in the nanoscale organisation and functional signalling of ryanodine receptor clusters in cardiomyocytes. J Cell Sci 2016;129:4388-98.
38. Reynolds JO, Quick AP, Wang Q, et al. Junctophilin-2 gene therapy rescues heart failure by normalizing RyR2-mediated Ca2+ release. Int J Cardiol 2016;225:371-80.
39. Lyu Y, Verma VK, Lee Y, et al. Remodeling of t-system and proteins underlying excitation-contraction coupling in aging versus failing human heart. NPJ Aging Mech Dis 2021;7:16.
40. Choi S, Vivas O, Baudot M, Moreno CM. Aging alters the formation and functionality of signaling microdomains between L-type calcium channels and β2-adrenergic receptors in cardiac pacemaker cells. Front Physiol 2022;13:805909.
41. Luo X, Yu W, Liu Z, et al. Ageing increases cardiac electrical remodelling in rats and mice via NOX4/ROS/CaMKII-mediated calcium signalling. Oxid Med Cell Longev 2022;2022:8538296.
42. Anyukhovsky EP, Sosunov EA, Plotnikov A, et al. Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res 2002;54:462-9.
43. Herraiz-Martínez A, Álvarez-García J, Llach A, et al. Ageing is associated with deterioration of calcium homeostasis in isolated human right atrial myocytes. Cardiovasc Res 2015;106:76-86.
44. Feridooni HA, Dibb KM, Howlett SE. How cardiomyocyte excitation, calcium release and contraction become altered with age. J Mol Cell Cardiol 2015;83:62-72.
45. Joseph LC, Reyes MV, Homan EA, et al. The mitochondrial calcium uniporter promotes arrhythmias caused by high-fat diet. Sci Rep 2021;11:17808.
46. Liu C, Bai J, Dan Q, et al. Mitochondrial dysfunction contributes to aging-related atrial fibrillation. Oxid Med Cell Longev 2021;2021:5530293.
47. Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clin Interv Aging 2018;13:757-72.
48. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300.
49. Martínez de Toda I, Ceprián N, Díaz-Del Cerro E, De la Fuente M. The role of immune cells in oxi-inflamm-aging. Cells 2021;10:2974.
50. Gladyshev VN. The free radical theory of aging is dead. Long live the damage theory! Antioxid Redox Signal 2014;20:727-31.
51. Tan BL, Norhaizan ME, Liew WP, Sulaiman Rahman H. Antioxidant and oxidative stress: a mutual interplay in age-related diseases. Front Pharmacol 2018;9:1162.
52. Maldonado E, Morales-Pison S, Urbina F, Solari A. Aging hallmarks and the role of oxidative stress. Antioxidants 2023;12:651.
53. Iakovou E, Kourti M. A comprehensive overview of the complex role of oxidative stress in aging, the contributing environmental stressors and emerging antioxidant therapeutic interventions. Front Aging Neurosci 2022;14:827900.
54. Peoples JN, Saraf A, Ghazal N, Pham TT, Kwong JQ. Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med 2019;51:1-13.
55. Reilly SN, Jayaram R, Nahar K, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011;124:1107-17.
56. Rudolph V, Andrié RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010;16:470-4.
57. Youn JY, Zhang J, Zhang Y, et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol 2013;62:72-9.
58. Xie W, Santulli G, Reiken SR, et al. Mitochondrial oxidative stress promotes atrial fibrillation. Sci Rep 2015;5:11427.
59. D'Oria R, Schipani R, Leonardini A, et al. The role of oxidative stress in cardiac disease: from physiological response to injury factor. Oxid Med Cell Longev 2020;2020:5732956.
60. Liu H, Wang Q, Liu D, et al. Manganese superoxide dismutase as a novel oxidative stress biomarker for predicting paroxysmal atrial fibrillation. J Clin Med 2022;11:5131.
61. Kim YH, Lim DS, Lee JH, et al. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp Mol Med 2003;35:336-49.
62. Kozakiewicz M, Kornatowski M, Krzywińska O, Kędziora-Kornatowska K. Changes in the blood antioxidant defense of advanced age people. Clin Interv Aging 2019;14:763-71.
63. Watts M, Kolluru GK, Dherange P, et al. Decreased bioavailability of hydrogen sulfide links vascular endothelium and atrial remodeling in atrial fibrillation. Redox Biol 2021;38:101817.
64. Tesauro M, Mauriello A, Rovella V, et al. Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med 2017;281:471-82.
65. Chong E, Chang SL, Hsiao YW, et al. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation. Heart Rhythm 2015;12:1046-56.
66. Dong Q, Wu Z, Li X, et al. Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca2+ cycling proteins. J Transl Med 2014;12:323.
67. Csengeri D, Sprünker NA, Di Castelnuovo A, et al. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes. Eur Heart J 2021;42:1170-7.
68. Baczkó I, Light PE. Resveratrol and derivatives for the treatment of atrial fibrillation. Ann N Y Acad Sci 2015;1348:68-74.
69. Wang C, Pan Z. Hydrogen-rich saline mitigates pressure overload-induced cardiac hypertrophy and atrial fibrillation in rats via the JAK-STAT signalling pathway. J Int Med Res 2020;48:300060520936415.
70. Mighiu AS, Recalde A, Ziberna K, et al. Inducibility, but not stability, of atrial fibrillation is increased by NOX2 overexpression in mice. Cardiovasc Res 2021;117:2354-64.
71. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005;97:629-36.
72. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006;114:1455-61.
73. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004;110:2313-9.
74. Zheng Z, Jayaram R, Jiang L, et al. Perioperative rosuvastatin in cardiac surgery. N Engl J Med 2016;374:1744-53.
75. Murphy C, Deplazes E, Cranfield CG, Garcia A. The role of structure and biophysical properties in the pleiotropic effects of statins. Int J Mol Sci 2020;21:8745.
76. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011;342:d1250.
77. El Assar M, Álvarez-Bustos A, Sosa P, Angulo J, Rodríguez-Mañas L. Effect of physical activity/exercise on oxidative stress and inflammation in muscle and vascular aging. Int J Mol Sci 2022;23:8713.
78. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation 2008;118:800-7.
79. Elliott AD, Verdicchio CV, Mahajan R, et al. An exercise and physical activity program in patients with atrial fibrillation: the ACTIVE-AF randomized controlled trial. JACC Clin Electrophysiol 2023;9:455-65.
80. Barth AS, Merk S, Arnoldi E, et al. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res 2005;96:1022-9.
81. Mayr M, Yusuf S, Weir G, et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 2008;51:585-94.
82. Huang Y, Lin Q, Zhou Y, et al. Amino acid profile alteration in age-related atrial fibrillation. J Transl Med 2024;22:259.
83. Pool L, Wijdeveld LFJM, de Groot NMS, Brundel BJJM. The role of mitochondrial dysfunction in atrial fibrillation: translation to druggable target and biomarker discovery. Int J Mol Sci 2021;22:8463.
84. Brand MD, Orr AL, Perevoshchikova IV, Quinlan CL. The role of mitochondrial function and cellular bioenergetics in ageing and disease. Br J Dermatol 2013;169:1-8.
85. Lima T, Li TY, Mottis A, Auwerx J. Pleiotropic effects of mitochondria in aging. Nat Aging 2022;2:199-213.
86. Chistiakov DA, Sobenin IA, Revin VV, Orekhov AN, Bobryshev YV. Mitochondrial aging and age-related dysfunction of mitochondria. Biomed Res Int 2014;2014:238463.
87. Miwa S, Kashyap S, Chini E, von Zglinicki T. Mitochondrial dysfunction in cell senescence and aging. J Clin Invest 2022;132:e158447.
88. Thiedemann KU, Ferrans VJ. Left atrial ultrastructure in mitral valvular disease. Am J Pathol 1977;89:575-604.
89. Ausma J, Wijffels M, Thoné F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997;96:3157-63.
90. Mason FE, Pronto JRD, Alhussini K, Maack C, Voigt N. Cellular and mitochondrial mechanisms of atrial fibrillation. Basic Res Cardiol 2020;115:72.
91. Liang H, Ward WF. PGC-1α: a key regulator of energy metabolism. Adv Physiol Educ 2006;30:145-51.
92. Valli H, Ahmad S, Chadda KR, et al. Age-dependent atrial arrhythmic phenotype secondary to mitochondrial dysfunction in Pgc-1β deficient murine hearts. Mech Ageing Dev 2017;167:30-45.
93. Harada M, Melka J, Sobue Y, Nattel S. Metabolic considerations in atrial fibrillation - mechanistic insights and therapeutic opportunities. Circ J 2017;81:1749-57.
94. Zhang D, Hu X, Li J, et al. DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD+ depletion in experimental atrial fibrillation. Nat Commun 2019;10:1307.
95. Mangerich A, Bürkle A. Pleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammation. Oxid Med Cell Longev 2012;2012:321653.
96. Hosseini L, Vafaee MS, Mahmoudi J, Badalzadeh R. Nicotinamide adenine dinucleotide emerges as a therapeutic target in aging and ischemic conditions. Biogerontology 2019;20:381-95.
97. Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside-the current state of research and therapeutic uses. Nutrients 2020;12:1616.
98. Pool L, Knops P, Manintveld OC, et al. The HF-AF ENERGY trial: nicotinamide riboside for the treatment of atrial fibrillation in heart failure patients. Cardiovasc Drugs Ther 2023;37:1243-8.
99. Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One 2017;12:e0186459.
100. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018;14:576-90.
101. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018;15:505-22.
102. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91.
103. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012;60:2263-70.
104. Dobrev D, Heijman J, Hiram R, Li N, Nattel S. Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology. Nat Rev Cardiol 2023;20:145-67.
105. Nso N, Bookani KR, Metzl M, Radparvar F. Role of inflammation in atrial fibrillation: a comprehensive review of current knowledge. J Arrhythm 2021;37:1-10.
106. Zhou X, Dudley SC Jr. Evidence for inflammation as a driver of atrial fibrillation. Front Cardiovasc Med 2020;7:62.
107. Jansen HJ, Bohne LJ, Gillis AM, Rose RA. Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease. Heart Rhythm O2 2020;1:147-59.
108. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J 2017;38:1717-27.
109. Rossiello F, Jurk D, Passos JF, d'Adda di Fagagna F. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol 2022;24:135-47.
110. Sweeney M, Cook SA, Gil J. Therapeutic opportunities for senolysis in cardiovascular disease. FEBS J 2023;290:1235-55.
111. Triana-Martínez F, Picallos-Rabina P, Da Silva-Álvarez S, et al. Identification and characterization of cardiac glycosides as senolytic compounds. Nat Commun 2019;10:4731.
112. Huang Y, Liu B, Sinha SC, Amin S, Gan L. Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders. Mol Neurodegener 2023;18:79.
113. Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol 2021;21:548-69.
114. McHugh D, Gil J. Senescence and aging: causes, consequences, and therapeutic avenues. J Cell Biol 2018;217:65-77.
115. Sebastian-Valverde M, Pasinetti GM. The NLRP3 inflammasome as a critical actor in the inflammaging process. Cells 2020;9:1552.
117. Song J, Navarro-Garcia JA, Wu J, et al. Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation. J Clin Invest 2023;133:e167517.
118. Zhang Y, Zhang S, Li B, et al. Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome. Cardiovasc Res 2022;118:785-97.
119. Yao C, Veleva T, Scott L Jr, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation 2018;138:2227-42.
120. Marín-Aguilar F, Lechuga-Vieco AV, Alcocer-Gómez E, et al. NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice. Aging Cell 2020;19:e13050.
121. Willar B, Tran KV, Fitzgibbons TP. Epicardial adipocytes in the pathogenesis of atrial fibrillation: An update on basic and translational studies. Front Endocrinol 2023;14:1154824.
122. Patel KHK, Hwang T, Se Liebers C, Ng FS. Epicardial adipose tissue as a mediator of cardiac arrhythmias. Am J Physiol Heart Circ Physiol 2022;322:H129-44.
123. Abe I, Teshima Y, Kondo H, et al. Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm 2018;15:1717-27.
124. Kira S, Abe I, Ishii Y, et al. Role of angiopoietin-like protein 2 in atrial fibrosis induced by human epicardial adipose tissue: Analysis using an organo-culture system. Heart Rhythm 2020;17:1591-601.
125. Meulendijks ER, Al-Shama RFM, Kawasaki M, et al. Atrial epicardial adipose tissue abundantly secretes myeloperoxidase and activates atrial fibroblasts in patients with atrial fibrillation. J Transl Med 2023;21:366.
126. Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases. Signal Transduct Target Ther 2022;7:135.
127. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 2015;26:26191.
128. Wilmanski T, Diener C, Rappaport N, et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat Metab 2021;3:274-86.
129. Gawałko M, Agbaedeng TA, Saljic A, et al. Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. Cardiovasc Res 2022;118:2415-27.
130. Yu L, Meng G, Huang B, et al. A potential relationship between gut microbes and atrial fibrillation: trimethylamine N-oxide, a gut microbe-derived metabolite, facilitates the progression of atrial fibrillation. Int J Cardiol 2018;255:92-8.
131. Svingen GFT, Zuo H, Ueland PM, et al. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation. Int J Cardiol 2018;267:100-6.
132. Zuo K, Yin X, Li K, et al. Different types of atrial fibrillation share patterns of gut microbiota dysbiosis. mSphere 2020;5:e00071-20.
133. Palmu J, Börschel CS, Ortega-Alonso A, et al. Gut microbiome and atrial fibrillation-results from a large population-based study. EBioMedicine 2023;91:104583.
134. Eghbali M, Eghbali M, Robinson TF, Seifter S, Blumenfeld OO. Collagen accumulation in heart ventricles as a function of growth and aging. Cardiovasc Res 1989;23:723-9.
136. Trial J, Cieslik KA. Changes in cardiac resident fibroblast physiology and phenotype in aging. Am J Physiol Heart Circ Physiol 2018;315:H745-55.
137. Cieslik KA, Trial J, Entman ML. Defective myofibroblast formation from mesenchymal stem cells in the aging murine heart rescue by activation of the AMPK pathway. Am J Pathol 2011;179:1792-806.
138. Zhang R, Zhang YY, Huang XR, et al. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 2010;55:953-60.
139. Cieslik KA, Trial J, Carlson S, Taffet GE, Entman ML. Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels. FASEB J 2013;27:1761-71.
140. Neilan TG, Coelho-Filho OR, Shah RV, et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. JACC Cardiovasc Imaging 2013;6:672-83.
142. King JB, Azadani PN, Suksaranjit P, et al. Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation. J Am Coll Cardiol 2017;70:1311-21.
143. Ni L, Lahiri SK, Nie J, et al. Genetic inhibition of nuclear factor of activated T-cell c2 prevents atrial fibrillation in CREM transgenic mice. Cardiovasc Res 2022;118:2805-18.
144. Scholz B, Schulte JS, Hamer S, et al. HDAC (histone deacetylase) inhibitor valproic acid attenuates atrial remodeling and delays the onset of atrial fibrillation in mice. Circ Arrhythm Electrophysiol 2019;12:e007071.
145. Zhao S, Hulsurkar MM, Lahiri SK, et al. Atrial proteomic profiling reveals a switch towards profibrotic gene expression program in CREM-IbΔC-X mice with persistent atrial fibrillation. J Mol Cell Cardiol 2024;190:1-12.
146. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circ Res 2016;118:1021-40.
147. Cieslik KA, Trial J, Entman ML. Mesenchymal stem cell-derived inflammatory fibroblasts promote monocyte transition into myeloid fibroblasts via an IL-6-dependent mechanism in the aging mouse heart. FASEB J 2015;29:3160-70.
148. Vidal R, Wagner JUG, Braeuning C, et al. Transcriptional heterogeneity of fibroblasts is a hallmark of the aging heart. JCI Insight 2019;4:131092.
149. Xie J, Chen Y, Hu C, et al. Premature senescence of cardiac fibroblasts and atrial fibrosis in patients with atrial fibrillation. Oncotarget 2017;8:57981-90.
150. Nicin L, Wagner JUG, Luxán G, Dimmeler S. Fibroblast-mediated intercellular crosstalk in the healthy and diseased heart. FEBS Lett 2022;596:638-54.
151. Tsuruda T, Jougasaki M, Boerrigter G, et al. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res 2002;90:128-34.
152. López-Andrés N, Calvier L, Labat C, et al. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension 2013;61:120-9.
153. Moreira LM, Takawale A, Hulsurkar M, et al. Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia. Nature 2020;587:460-5.
154. Gao XY, Lai YY, Luo XS, et al. Acetyltransferase p300 regulates atrial fibroblast senescence and age-related atrial fibrosis through p53/Smad3 axis. Aging Cell 2023;22:e13743.
155. Ghosh AK. Acetyltransferase p300 is a putative epidrug target for amelioration of cellular aging-related cardiovascular disease. Cells 2021;10:2839.
156. Li Y, Fang G, Cao W, et al. Ezh2 inhibits replicative senescence of atrial fibroblasts through promotion of H3K27me3 in the promoter regions of CDKN2a and Timp4 genes. J Inflamm Res 2022;15:4693-708.
157. Kinser HE, Pincus Z. MicroRNAs as modulators of longevity and the aging process. Hum Genet 2020;139:291-308.
158. Adam O, Löhfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012;107:278.
159. Jazbutyte V, Fiedler J, Kneitz S, et al. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age 2013;35:747-62.
160. Luo X, Pan Z, Shan H, et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest 2013;123:1939-51.
161. Yuan K, Zhao P, Wang L. Molecular mechanism of atrial remodeling in patients with aging atrial fibrillation under the expression of microRNA-1 and microRNA-21. Bioengineered 2021;12:12905-16.
162. Reilly SN, Liu X, Carnicer R, et al. Up-regulation of miR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase. Sci Transl Med 2016;8:340ra74.
163. Martinez EC, Lilyanna S, Wang P, et al. MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease. J Mol Cell Cardiol 2017;112:27-39.
164. Huang S, Zhang L, Song J, et al. Long noncoding RNA MALAT1 mediates cardiac fibrosis in experimental postinfarct myocardium mice model. J Cell Physiol 2019;234:2997-3006.
165. Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med 2019;33:363-82.
166. Wo Y, Guo J, Li P, Yang H, Wo J. Long non-coding RNA CHRF facilitates cardiac hypertrophy through regulating Akt3 via miR-93. Cardiovasc Pathol 2018;35:29-36.
167. Wang K, Liu F, Zhou LY, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 2014;114:1377-88.
168. Trembinski DJ, Bink DI, Theodorou K, et al. Aging-regulated anti-apoptotic long non-coding RNA Sarrah augments recovery from acute myocardial infarction. Nat Commun 2020;11:2039.
169. Zangrando J, Zhang L, Vausort M, et al. Identification of candidate long non-coding RNAs in response to myocardial infarction. BMC Genomics 2014;15:460.
170. Zhu Y, Zhu L, Wang X, Jin H. RNA-based therapeutics: an overview and prospectus. Cell Death Dis 2022;13:644.
171. Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet 2022;23:265-80.
172. Brundel BJ, Henning RH, Ke L, van Gelder IC, Crijns HJ, Kampinga HH. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol 2006;41:555-62.
173. van Marion DMS, Dorsch L, Hoogstra-Berends F, et al. Oral geranylgeranylacetone treatment increases heat shock protein expression in human atrial tissue. Heart Rhythm 2020;17:115-22.
174. Brundel BJ, Shiroshita-Takeshita A, Qi X, et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 2006;99:1394-402.
175. Versaci F, Valenti V, Forte M, et al. Aging-related decline of autophagy in patients with atrial fibrillation-a post hoc analysis of the ATHERO-AF study. Antioxidants 2022;11:698.
176. Wiersma M, Meijering RAM, Qi XY, et al. Endoplasmic reticulum stress is associated with autophagy and cardiomyocyte remodeling in experimental and human atrial fibrillation. J Am Heart Assoc 2017;6:e006458.
177. Brundel BJ, Ausma J, van Gelder IC, et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 2002;54:380-9.
179. Hägg S, Jylhävä J. Sex differences in biological aging with a focus on human studies. Elife 2021;10:e63425.
180. Odening KE, Deiß S, Dilling-Boer D, et al. Mechanisms of sex differences in atrial fibrillation: role of hormones and differences in electrophysiology, structure, function, and remodelling. Europace 2019;21:366-76.
181. Roberts JD, Vittinghoff E, Lu AT, et al. Epigenetic age and the risk of incident atrial fibrillation. Circulation 2021;144:1899-911.
